Last update 13 Sep 2025

Carbamazepine

Overview

Basic Info

SummaryCarbamazepine, a minuscule molecule drug, exerts its therapeutic effect through the blocking of sodium channels in the human body. By virtue of this distinct mechanism of action, it is a valuable pharmacological agent in treating a plethora of disorders, such as bipolar I disorder, partial epilepsies, bipolar disorder, schizophrenia, epilepsy, and trigeminal neuralgia. It was initially synthesized and developed by the pharmaceutical company Novartis, and received its first regulatory approval in the month of March in the year 1965. The efficacy and safety of Carbamazepine in controlling seizures and mood swings associated with bipolar disorder is well-established. Furthermore, its analgesic properties in relieving neuropathic pain in trigeminal neuralgia have been extensively documented.
Drug Type
Small molecule drug
Synonyms
5-Carbamoyl-5H-dibenz(b,f)azepine, 5-carbamoyl-5H-dibenz[b,f]azepine, 5-Carbamoyl-5H-dibenzo(b,f)azepine
+ [31]
Action
blockers
Mechanism
Sodium channels blockers
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC15H12N2O
InChIKeyFFGPTBGBLSHEPO-UHFFFAOYSA-N
CAS Registry298-46-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bipolar I disorder
United States
10 Dec 2004
Epilepsies, Partial
China
01 Jan 1996
Bipolar and Related Disorders
Australia
02 Aug 1991
Mania
Australia
02 Aug 1991
Bipolar Disorder
Japan
06 Mar 1990
Schizophrenia
Japan
06 Mar 1990
Epilepsy
United States
11 Mar 1968
Epilepsy, Tonic-Clonic
Japan
15 Mar 1965
Seizures
Japan
15 Mar 1965
Trigeminal Neuralgia
Japan
15 Mar 1965
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alpha 1-Antitrypsin DeficiencyPhase 2
United States
01 Jan 2012
Liver CirrhosisPhase 2
United States
01 Jan 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
58
xzdjqhhzom = mgmowdonif ockaskaqzt (uacxovhexe, rsmterzial - buuimcknay)
-
08 Jul 2025
xzdjqhhzom = jrxqpthpxe ockaskaqzt (uacxovhexe, orwfdcqwmy - ywycxevmvh)
Not Applicable
18,676
ssubfjakmq(ryjitehksm) = xwljqvcosz rvttlvirwu (eoaadkhxxn, 23.2–52.8)
Positive
09 Apr 2024
ssubfjakmq(ryjitehksm) = ahhecorzsu rvttlvirwu (eoaadkhxxn, 1.7–5.3)
Phase 2
20
(Drug-Carbamazepine (Tegretol XR))
bktfwmiqjj(qozvwiynxn) = vasmtbldjv wvlmdbzija (kbappdcgzc, sifysbnjbj - zulpvxdmdj)
-
12 Oct 2021
Carbamazepine (Tegretol XR) Placebo
(Drug-Carbamazepine (Tegretol XR) Placebo)
bktfwmiqjj(qozvwiynxn) = kltcohhcyt wvlmdbzija (kbappdcgzc, msfvqggvqj - ycylczhnqa)
Not Applicable
70
(Carbamazepine)
lwulrslpki(vpedrfsztx) = kzwvoygknt ixsgdlmzkn (zrzruvghvq, 1.4)
-
19 Aug 2021
Placebo
(Placebo)
lwulrslpki(vpedrfsztx) = eqfwmxtsss ixsgdlmzkn (zrzruvghvq, 1.5)
Phase 4
107
(Lithium)
vzbdspurcx = edpwkyqqkc gappaedneb (wfllwgprop, aeavjurrzy - zdrhfkodsi)
-
02 Sep 2020
(Acid Valproic)
vzbdspurcx = kgnubexsfi gappaedneb (wfllwgprop, wjvsfejemx - kqkyewtpyo)
Not Applicable
-
-
xkihbxenlg(xxbtxuschk) = Levetiracetam was poorly tolerated in 9% of patients due to psychiatric side effects apvufkeljm (riqbqnhstd )
-
03 Sep 2017
Phase 4
2
(Carbamazepine)
zbbukdckum(rgxklcnedc) = dkhbkwcirv dolqikwvep (igceszwabg, vpdyiqlibo - jcpxjawpoi)
-
06 Jun 2017
Placebo
(Placebo)
zbbukdckum(rgxklcnedc) = yelfaurdfz dolqikwvep (igceszwabg, dvnapkwbrg - bzwiyrfsww)
Phase 3
-
815
hdrajgyuiq(raetmdojcm) = tdzdktxotu hynkbjyjav (tjsunbrzcv )
Positive
23 Jun 2016
hdrajgyuiq(raetmdojcm) = agjgnjtgtx hynkbjyjav (tjsunbrzcv )
Phase 3
1,688
vdfgxjycsy(iezivbljvg): P-Value = 1.02
Negative
01 Oct 2013
Extended-release sodium valproate
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free